JP2021504336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504336A5 JP2021504336A5 JP2020528107A JP2020528107A JP2021504336A5 JP 2021504336 A5 JP2021504336 A5 JP 2021504336A5 JP 2020528107 A JP2020528107 A JP 2020528107A JP 2020528107 A JP2020528107 A JP 2020528107A JP 2021504336 A5 JP2021504336 A5 JP 2021504336A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- antibody
- subject
- immunotherapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 20
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 11
- 229960002204 daratumumab Drugs 0.000 claims description 7
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims description 4
- 229960000548 alemtuzumab Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 229960002450 ofatumumab Drugs 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229960002087 pertuzumab Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229960005267 tositumomab Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000036039 immunity Effects 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023188161A JP2024016156A (ja) | 2017-11-24 | 2023-11-02 | 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1719561.1 | 2017-11-24 | ||
| GBGB1719561.1A GB201719561D0 (en) | 2017-11-24 | 2017-11-24 | Vaccine to enhance ADCC |
| GBGB1806575.5A GB201806575D0 (en) | 2018-04-23 | 2018-04-23 | Vaccine to enhance adcc |
| GB1806575.5 | 2018-04-23 | ||
| PCT/EP2018/082427 WO2019101954A1 (en) | 2017-11-24 | 2018-11-23 | Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188161A Division JP2024016156A (ja) | 2017-11-24 | 2023-11-02 | 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504336A JP2021504336A (ja) | 2021-02-15 |
| JP2021504336A5 true JP2021504336A5 (enExample) | 2022-01-04 |
Family
ID=64572324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528107A Pending JP2021504336A (ja) | 2017-11-24 | 2018-11-23 | 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化 |
| JP2023188161A Pending JP2024016156A (ja) | 2017-11-24 | 2023-11-02 | 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188161A Pending JP2024016156A (ja) | 2017-11-24 | 2023-11-02 | 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200299401A1 (enExample) |
| EP (1) | EP3713645A1 (enExample) |
| JP (2) | JP2021504336A (enExample) |
| CN (1) | CN111372656A (enExample) |
| WO (1) | WO2019101954A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3472180A1 (en) * | 2016-06-21 | 2019-04-24 | IO Biotech APS | Pdl1 peptides for use in cancer vaccines |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2768524T (lt) * | 2011-10-17 | 2022-07-25 | Io Biotech Aps | Pd-l1 grindžiama imunoterapija |
| FI3423087T3 (fi) * | 2016-03-04 | 2023-12-15 | Io Biotech Aps | Syövän vastainen yhdistelmähoito |
-
2018
- 2018-11-23 US US16/765,654 patent/US20200299401A1/en not_active Abandoned
- 2018-11-23 JP JP2020528107A patent/JP2021504336A/ja active Pending
- 2018-11-23 CN CN201880075234.9A patent/CN111372656A/zh active Pending
- 2018-11-23 WO PCT/EP2018/082427 patent/WO2019101954A1/en not_active Ceased
- 2018-11-23 EP EP18812101.6A patent/EP3713645A1/en active Pending
-
2023
- 2023-10-20 US US18/491,464 patent/US20240052053A1/en active Pending
- 2023-11-02 JP JP2023188161A patent/JP2024016156A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525128A5 (enExample) | ||
| ECSP15007345A (es) | Métodos para el tratamiento de infecciones de hepatitis b y hepatitis d | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| JP2018502120A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX373884B (es) | Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta. | |
| JP2019511222A5 (enExample) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2019510001A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| JP2016528247A5 (enExample) | ||
| JP2015522252A5 (enExample) | ||
| AR068532A1 (es) | Inhibicion de angiogenesis | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| WO2008064299A3 (en) | Methods of reducing porcine circovirus-associated disease outbreaks | |
| JP2015525798A5 (enExample) | ||
| WO2014007982A3 (en) | C-terminal and central epitope a-beta antibodies | |
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 | |
| MX392496B (es) | Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica. | |
| JP2018529661A5 (enExample) | ||
| JP2019520316A5 (enExample) |